{"schema_version":"secwatch.filing_event.v1","accession":"0001376339-25-000087","form_type":"8-K","ticker":"MDXG","cik":"0001376339","company_name":"MIMEDX GROUP, INC.","filed_at":"2025-07-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.842809+00:00","generated_at":"2026-05-17T22:56:25.446086+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"MiMedX Q2 net sales $99M record, up 13% YoY; raises 2025 growth to low double-digits","bullets":["Net sales $99M (record), +13% YoY; GAAP net income $10M ($0.06 EPS); prior year included $9.3M settlement benefit.","Adjusted EBITDA $24M (25% margin); cash $119M, up $15M from Dec 2024.","Wound sales +12%, Surgical +15% YoY; driven by new products CELERA, EMERGE, HELIOGEN.","Raises 2025 net sales growth outlook to low double-digits; reaffirms adjusted EBITDA margin above 20%.","CEO supports CMS proposal to overhaul skin substitute reimbursement; engaging in comment period."],"urls":{"canonical":"https://secwatch.observer/filing/0001376339-25-000087","json":"https://secwatch.observer/filing/0001376339-25-000087.json","markdown":"https://secwatch.observer/filing/0001376339-25-000087.md","text":"https://secwatch.observer/filing/0001376339-25-000087.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1376339/000137633925000087/0001376339-25-000087-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1376339/000137633925000087/mdxg-20250730.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T22:56:25.446086+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}